Sanofi-Aventis Deutschland GmbH

Importance of OCT2 and MATE1 for the Cimetidine-Metformin Interaction: Insights from Investigations of Polarized Transport in Single- And Double-Transfected MDCK Cells with a Focus on Perpetrator Disposition (2018) Mueller F, Weitz D, Mertsch K, König J, Fromm M Journal article The hpCADD NDDO Hamiltonian: Parametrization (2017) Thomas HB, Hennemann M, Kibies P, Hoffgaard F, Guessregen S, Hessler G, Kast SM, Clark T Journal article Contribution of MATE1 to Renal Secretion of the NMDA Receptor Antagonist Memantine (2017) Mueller F, Weitz D, Derdau V, Sandvoss M, Mertsch K, König J, Fromm M Journal article Systems biology of the IMIDIA biobank from organ donors and pancreatectomised patients defines a novel transcriptomic signature of islets from individuals with type 2 diabetes (2017) Solimena M, Schulte AM, Marselli L, Ehehalt F, Richter D, Kleeberg M, Mziaut H, et al. Journal article Quantum Mechanics-Based Properties for 3D-QSAR (2013) El Kerdawy A, Güssregen S, Matter H, Hennemann M, Clark T Journal article 3D-QSAR Based on Quantum-Chemical Molecular Fields: Toward an Improved Description of Halogen Interactions (2012) Güssregen S, Matter H, Hessler G, Müller M, Schmidt F, Clark T Journal article Methylglyoxal modification of Na v 1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy (2012) Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, Sauer S, et al. Journal article Erratum: Methylglyoxal modification of Na v 1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy (Nature Medicine (2012) 18 (926-933)) (2012) Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, Sauer S, et al. Journal article, Erratum Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on Sarcopenia (2011) Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Van Kan GA, et al. Journal article Wirtschaftlichkeit einer frühen basalunterstützten oralen Therapie (BOT) mit Insulin glargin im Vergleich zu einer Therapieeskalation mit einem DPP-4-Hemmer bei Patien-ten mit Typ-2-Diabetes unter realen Versorgungsbedingungen in Deutschland (2011) Kobusch D, Dippel FW, Kostev K, Schöffski O Journal article